Evidence map›Paper›PMID 36483203›Full record

ArticleFrontiers in microbiology2022

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria.

Michaela Simon, Roman G Gerlach, Yvonne Pfeifer, Niels Pfennigwerth, Sören G Gatermann, Agnes Schröder, Andreas Hiergeist, Axel Hamprecht, Tamara Rügamer, André Gessner and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Michaela SimonInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Regensburg, Germany.
Roman G GerlachMikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen- Nürnberg, Erlangen, Germany.
Yvonne PfeiferFG13 Nosocomial Pathogens and Antibiotic Resistance, Robert Koch Institute, Wernigerode, Germany.
Niels PfennigwerthDepartment of Medical Microbiology, German National Reference Centre for Multidrug-Resistant Gram-negative Bacteria, Ruhr-University Bochum, Bochum, Germany.
Sören G GatermannDepartment of Medical Microbiology, German National Reference Centre for Multidrug-Resistant Gram-negative Bacteria, Ruhr-University Bochum, Bochum, Germany.
Agnes SchröderInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Regensburg, Germany.
Andreas HiergeistInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Regensburg, Germany.
Axel HamprechtInstitute for Medical Microbiology, Immunology, and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Tamara RügamerInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Regensburg, Germany.
André GessnerInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Regensburg, Germany.
Jonathan JantschInstitute of Clinical Microbiology and Hygiene, University Hospital of Regensburg, Regensburg, Germany.
University Hospital Regensburg · DERuhr University Bochum · DERobert Koch Institute · DEUniversitätsklinikum Erlangen · DEUniversity Hospital Cologne · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-automated antimicrobial susceptibility testing system regarding its capability to detect phenotypic ceftazidime-avibactam resistance in 176 carbapenem-resistant, metallo-β-lactamase-producing Enterobacterales and

Indexed as

antimicrobial susceptibility testingceftazidime-avibactamEnterobacteralesmetallo-β-lactamasesMicronautPhoenixPseudomonas aeruginosazinc

Identifiers

PMID36483203
PMCPMC9723239
OpenAlexW4311020667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.